| The Panel on Antiretroviral Guidelines for Adults and Adolescents (the Panel) updated the following section |
Updates to the Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV | The Panelon Antiretroviral Guidelines for Adults and Adolescents (the Panel) updated the following section of theGuidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Highlights are summarized below: Early (Acute and Recent) HIV Infection In this revision, the Panelsuggested a HIV RNA level of <10,000copies/mL in a person suspected to have acute HIV may represent a false-positive test result. The Panel noted that given the improved sensitivity and specificity of current HIV RNA tests in the presence of compatible symptoms or exposure history, even a low HIV RNA concentration (e.g., <3,000 copies/mL) in the setting ofanegative or indeterminate HIV antibody test result may represent acute HIV. The Panel noted that, in rare cases, a HIV RNA <3,000 copies/mL may represent a false-positive quantitative test result. In that case, repeat testing should be done to confirm the diagnosis.This section has been updated to revise this threshold. Further, the Panel also provided updated information regarding diagnosis of acute HIV in individuals who are receiving pre-exposure prophylaxis and subsequent initiation of antiretroviral therapy (ART). Discontinuation or Interruption of Antiretroviral Therapy This section has been updated to include discussions regarding discontinuation or interruption of long-acting antiretroviral drugs, including ibalizumab and the intramuscular formulations of cabotegravir andrilpivirine. The section also includes discussions regarding steps to take before and during ART interruption for people with HIV who participate in clinical trials that involve analytical treatment interruptions. For a complete list of updates, please seeWhat's New in the Guidelines. To view or download the guidelines, please see the Adult and Adolescent ARV Guidelines section of Clinical Infos website. The guidelines tables and recommendations can also be downloaded as separate PDF files. Clinical InfoWelcomes Your Feedbackon the latest revisions to theGuidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Please send your comments with the subject line Adult and Adolescent ARV Guidelines to [email protected] by February 10, 2022. |
|
|
|
|
You are subscribed as [email protected]. Update your subscriptions, modify your password or email address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your email address to log in. If you have questions or problems with the subscription service, please visit the GovDelivery Subscriber Help Center at https://insights.govdelivery.com/Communications/Subscriber_Help_Center.
This service is provided in collaboration with NIHs Office of AIDS Research and HHS Office of Infectious Disease and HIV/AIDS Policy/HIV.gov.
| This email was sent to [email protected] using GovDelivery Communications Cloud on behalf of: HIVinfo 8600 Rockville Pike Bethesda, MD 20894 888-346-3656 | |
